Healthcare Professional

CG Oncology is committed to advancing science through clinical trials. Our lead candidate, cretostimogene grenadenorepvec, is an oncolytic immunotherapy with a dual mechanism of action. By encouraging patients to participate in clinical trials, together we can advance science and bring new treatment options to patients.

Learn more about CG Oncology’s ongoing Clinical Trials

Healthcare Professional

CG Oncology is committed to advancing science through clinical trials. Our lead candidate, cretostimogene grenadenorepvec is an oncolytic immunotherapy with a dual mechanism of action. By encouraging patients to participate in clinical trials, together we can advance science and bring new treatment options to patients.

Learn More

Videos

Slide One

Slide Two

Please watch these videos to learn more or share this Mechanism of Action video with your patients

Why Clinical Trials:

Clinical trials are really important both from a physician and a patient perspective. They allow us to push the field forward, but they also allow patients access to treatments and options where the alternative may be really impactful in their day-to-day life.

Sima P. Porten MD, MPH

Assistant Professor, Urology, University of California, San Francisco

Clinical Trials

Learn how CG Oncology is committed to diversity in our clinical trials.

Learn More

Resources

Download our resources to learn more about our work in developing a bladder-sparing therapeutic option for those affected by bladder cancer.

Learn More

Contact Us

For more information about our clinical trials, feel free to contact our team.

Learn More